Inventor · disambiguated record
Daniel A. Gamache
Also filed as: GAMACHE DANIEL · GAMACHE DANIEL A
38 granted patents·46 pending applications·595 citations·filing 1995–2018
98Inventor score
Top patents by PatentIndex Score
84 records- 0195US6872382B1Use of selective PDE IV inhibitors to treat dry eye disordersALCON INC·Filed 2002·Granted Mar 29, 2005·64 cites·4 claims
- 0292US6645978B1Lipoxin A4 and its analogs for the treatment of dry eyeALCON INC·Filed 2000·Granted Nov 11, 2003·39 cites·5 claims
- 0390US8791154B2High concentration olopatadine ophthalmic compositionGAMACHE DANIEL A·Filed 2012·Granted Jul 29, 2014·28 cites·27 claims
- 0490US6353022B1Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disordersALCON UNIVERSAL LTD·Filed 2000·Granted Mar 5, 2002·38 cites·22 claims
- 0589US5696166ACompositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disordersFiled 1995·Granted Dec 9, 1997·93 cites·7 claims
- 0687US7923471B2Method of treating dry eye disorders and uveitisALCON INC·Filed 2005·Granted Apr 12, 2011·3 cites·9 claims
- 0786US8222227B2RNAi-mediated inhibition of histamine receptor H1-related conditionsYANNI JOHN M·Filed 2011·Granted Jul 17, 2012·6 cites·13 claims
- 0886US6174878B1Topical use of kappa opioid agonists to treat otic painALCON LAB INC·Filed 1999·Granted Jan 16, 2001·71 cites·15 claims
- 0985US8017592B2RNAi-mediated inhibition of histamine receptor H1-related conditionsALCON RES LTD·Filed 2007·Granted Sep 13, 2011·5 cites·13 claims
- 1084US7732421B2RNAI-mediated inhibition of tumor necrosis factor α-related conditionsALCON RES LTD·Filed 2007·Granted Jun 8, 2010·4 cites·12 claims
- 1184US5811438AEsters and amides of non-steroidal anti-inflammatory carboxylic acids which may be used as anti-oxidants, 5-lipoxygenase inhibitors and non-steroidal anti-inflammatory productsALCON LAB INC·Filed 1995·Granted Sep 22, 1998·53 cites·37 claims
- 1282US8048863B2RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditionsALCON RES LTD·Filed 2007·Granted Nov 1, 2011·3 cites·36 claims
- 1382US6429227B1Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disordersALCON UNIVERSAL LTD·Filed 2000·Granted Aug 6, 2002·20 cites·29 claims
- 1481US8138205B2Heteroarylalkoxy-substituted quinolone inhibitors of PDE4GOVEK STEVEN P·Filed 2009·Granted Mar 20, 2012·4 cites·19 claims
- 1581US6645994B1Method of treating dry eye disordersALCON INC·Filed 2002·Granted Nov 11, 2003·10 cites·6 claims
- 1681US5643943ASystemic administration of esters and amides of antioxidants which may be used as antioxidant prodrug therapy for oxidative and inflammatory pathogenesisALCON LAB INC·Filed 1995·Granted Jul 1, 1997·47 cites·16 claims
- 1780US9453220B2RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disordersARROWHEAD RES CORP·Filed 2014·Granted Sep 27, 2016·2 cites·8 claims
- 1879US9206428B2RNAi-mediated inhibition of histamine receptor H1-related conditionsARROWHEAD RES CORP·Filed 2013·Granted Dec 8, 2015·2 cites·17 claims
- 1978US8618278B2RNAi-mediated inhibition of histamine receptor H1-related conditionsYANNI JOHN M·Filed 2012·Granted Dec 31, 2013·2 cites·4 claims
- 2077US8673873B1RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disordersYANNI JOHN M·Filed 2009·Granted Mar 18, 2014·1 cites·6 claims
- 2177US6825232B2Use of hydroxyeicosatetraenoic acid compounds to treat ophthalmic inflammatory disordersALCON INC·Filed 2003·Granted Nov 30, 2004·7 cites·5 claims
- 2277US6638976B2Method of treating neurodegenerative disorders of the retina and optic nerve headALCON INC·Filed 2001·Granted Oct 28, 2003·10 cites·12 claims
- 2375US6353012B115-Hydroxyeicosatetraenoic acid-related compounds and methods of useALCON UNIVERSAL LTD·Filed 2000·Granted Mar 5, 2002·8 cites·11 claims
- 2474US7026296B2Methods of treating dry eye disordersALCON INC·Filed 2003·Granted Apr 11, 2006·5 cites·3 claims
- 2570US5686488APolyethoxylated castor oil products as anti-inflammatory agentsALCON LAB INC·Filed 1995·Granted Nov 11, 1997·33 cites·24 claims
- 2670US2008096852A1Use of oculosurface selective glucocorticoid in the treatment of dry eyeALCON INC·Filed 2007·Application pending·0 cites
- 2767US2019032061A1RNAi-Mediated Inhibition of Tumor Necrosis Factor Alpha-Related ConditionsARROWHEAD PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2866US9447419B2RNAi-mediated inhibition of tumor necrosis factor α-related conditionsARROWHEAD RES CORP·Filed 2014·Granted Sep 20, 2016·0 cites·12 claims
- 2966US6696453B2Use of NF-κB inhibitors to treat dry eye disordersALCON INC·Filed 2002·Granted Feb 24, 2004·2 cites·5 claims
- 3066US6191126B1Topical use of κ opioid agonists to treat ocular painALCON LAB INC·Filed 1997·Granted Feb 20, 2001·21 cites·4 claims
- 3164US9765340B2RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-related ocular disordersARROWHEAD PHARMACEUTICALS INC·Filed 2016·Granted Sep 19, 2017·0 cites·21 claims
- 3263US9371529B2RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditionsARROWHEAD RES CORP·Filed 2014·Granted Jun 21, 2016·0 cites·13 claims
- 3363US2006058277A1Use of oculosurface selective glucocorticoid in the treatment of dry eyeYANNI JOHN M·Filed 2005·Application pending·0 cites
- 3463US2004132704A1Use of oculosurface selective glucocorticoid in the treatment of dry eyeFiled 2003·Application pending·0 cites
- 3562US2009131449A1Use of trpv1 receptor antagonists for treating dry eye and ocular painALCON RES LTD·Filed 2008·Application pending·0 cites
- 3662US2009098136A1Use of tnf receptor antagonists for treating dry eyeALCON RES LTD·Filed 2008·Application pending·0 cites
- 3762US2013338213A1RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONSALCON RES LTD·Filed 2013·Application pending·0 cites
- 3861US9533053B2High concentration olopatadine ophthalmic compositionALCON RES LTD·Filed 2014·Granted Jan 3, 2017·0 cites·13 claims
- 3961US2016369283A1RNAi-Mediated Inhibition of Tumor Necrosis Factor Alpha-Related ConditionsARROWHEAD PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 4060US2006217325A1Treatment of dry eye restoring 15-lipoxygenase activity to ocular surface cellsALCON INC·Filed 2003·Application pending·0 cites
- 4160US2004248794A1Treatment of dry eye by restoring 15-lipoxygenase activity to ocular surface cellsFiled 2003·Application pending·0 cites
- 4260US2008139531A1Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repairALCON MFG LTD·Filed 2007·Application pending·0 cites
- 4359US2010120741A1Heterocyclic inhibitors of histamine receptors for the treatment of diseaseKALYPSYS INC·Filed 2009·Application pending·0 cites
- 4458US9745585B2RNAi-mediated inhibition of histamine receptor H1-related conditionsARROWHEAD RES CORP·Filed 2015·Granted Aug 29, 2017·0 cites·16 claims
- 4558US8541389B2RNAi-mediated inhibition of tumor necrosis factor α-related conditionsYANNI JOHN M·Filed 2011·Granted Sep 24, 2013·0 cites·6 claims
- 4658US7879905B25,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responsesALCON INC·Filed 2005·Granted Feb 1, 2011·0 cites·1 claims
- 4757US2006069075A1Methods for treating dry eyeGAMACHE DANIEL A·Filed 2005·Application pending·0 cites
- 4856US8865671B2RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditionsYANNI JOHN M·Filed 2011·Granted Oct 21, 2014·0 cites·21 claims
- 4956US2003109509A1Methods for treating dry eyeALCON INC·Filed 2002·Application pending·0 cites
- 5055US2016257963A1RNAi-MEDIATED INHIBITION OF SPLEEN TYROSINE KINASE-RELATED INFLAMMATORY CONDITIONSARROWHEAD PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
Showing the top 50 of 84 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Daniel A. Gamache files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →